Loading the player...
Identifying Patients At -Risk for Hereditary Cancers
Presentation Title: Identifying Patients at Risk for Hereditary Cancers: Tools that Transform your Practice
Presentation Objectives: At the conclusion of this presentation, participants should understand the following concepts related to hereditary cancer risk assessment and patient management:
1. How utilizing Cancer Family History (CFHx) can help determine appropriate screening intervals.
2. Why stratifying patients by risk categories will help you determine appropriate management and screening recommendations.
3. How to integrate a Hereditary Cancer Risk Assessment (HCRA) protocol into your center.
4. What to select when considering your hereditary cancer lab.
The Maine Osteopathic Association is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians.The Maine Osteopathic Association designates this program for a maximum of 1.0 AOA Category 1-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
MOA Grievance Policy: All grievances should be initially directed in writing to the MOA Executive Director by email to info@mainedo.org who will share them with the MOA's Program Committee. Grievances will receive a response within 30 days of receipt. If you do not receive a satisfactory response, you may notify the Council on Continuing Medical Education, AOA, 142 East Ontario St., Chicago, IL 60611.
Dr Kathryn Dalton, DO is the Medical Director of both Cape Cod Hospital’s Women’s Health Program and CUDA Women’s Health Center’s High Risk Breast Cancer Program. She is a General Surgeon in her clinical practice at Cape Cod Hospital in Hyannis, MA. Dr Dalton’s clinical interests include: Breast surgery, Oncoplastic breast surgery, Nipple sparing mastectomy, Hidden scar breast surgery, Minimally invasive abdominal surgery, Dermatologic surgery, Genetic Counseling and testing, Surveillance of high risk breast cancer patients, Clinical speaker for Myriad Genetics and on the Clinical advisory board for Counsyl.
Faculty Disclosure: Dr. Dalton is on the speaker’s bureau for Myriad Genetics, which could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation.
